Testing a new drug for people with VEXAS
Part of Bones, joints & muscles, Pain clinical trials.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years of age or older
- Have a confirmed UBA1 gene mutation (the genetic change linked to VEXAS)
- Have had at least two VEXAS symptoms (like fevers, rashes, joint pain) currently or in the last 6 months
- Be able to start a preventive treatment for a lung infection called PJP during the study if needed
- Not have active infections, certain viral infections (hepatitis B, C, HIV), or a recent history of most cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug momelotinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition. Participants will keep taking their usual steroids and may receive momelotinib or a placebo to see if it helps control the disease.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This study aims to find out how common VEXAS syndrome is and how it looks in people over 50 who have unexplained inflammation or blood issues. It helps doctors better recognize and diagnose this rare condition.
This study creates a national registry for people with VEXAS syndrome to track the disease and collect blood samples for research. Joining helps doctors learn more about VEXAS so they can better diagnose and treat it in the future.
This trial tests a drug called momelotinib for people with VEXAS syndrome, a rare inflammatory condition. The goal is to see if momelotinib can reduce symptoms and the need for steroids.
This study looks at how VEXAS syndrome affects your daily life and finances. It aims to understand the challenges you face so doctors can better support you.
Hear when a new VEXAS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.